The National Comprehensive Cancer Network® (NCCN®) Guidelines now recommend scalp cooling as a Category 2A treatment option for patients with ovarian cancer.
The NCCN Guidelines has updated the Clinical Practice Guidelines in oncology for Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 1.2020) to include scalp cooling as a Category 2A recommendation to reduce the incidence of alopecia for patients receiving chemotherapy with high rates of alopecia.
The comprehensive global cancer statistics from the International Agency for Research on Cancer indicate that there were over 295,000 new cases of ovarian cancer in 2018 across the World.
“Since the NCCN Clinical Practice Guidelines in oncology for breast cancer (Version 1.2019) was updated in 2019 to include scalp cooling as a Category 2A recommendation this further update to the treatment guideline for Ovarian Cancer is an additional key step toward increasing patient and provider access to scalp cooling. The NCCN Guidelines® are widely recognized by the majority of public and private payers as the benchmark for coverage and reimbursement policies in the US,” says Paxman’s CEO Richard Paxman.
“As the scalp cooling provider for many leading cancer centers in the US, Paxman anticipate this further update will help increase adoption of scalp cooling by US cancer centers and thereby growth in patient utilisation.”
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss.
This week the British company launched the world’s first patient focused website to guide people through every step of the cold capping process. Coldcap.com is a revolutionary global patient guide offering detailed supportive information accessible 24 hours a day / seven days a week from any location in the world.
Paxman is already the scalp cooling partner of choice for many leading cancer centers in the US. To date, Paxman has over 600 scalp cooling systems installed in the US across 40 states in 300 locations.
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 30 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.